- The FDA has not accepted Amarin's (AMRN) appeal regarding the rescission of the SPA for Vascepa's ANCHOR study.
- The company also says its "request for a meeting at a high level within the FDA regarding the appeal was not granted."
- AMRN says it plans to continue to pursue the appeal. (8-K)
- AMRN -12% premarket
at CNBC.com (Feb 28, 2014)